Quantifying long-term health and economic outcomes for survivors of group B Streptococcus invasive disease in infancy: protocol of a multi-country study in Argentina, India, Kenya, Mozambique and South Africa [version 2; peer review: 1 approved, 2 approved with reservations]

• Main Authors: Proma Paul, Simon R. Procter, Ziyaad Dangor, Quique Bassat, Amina Abubakar, Sridhar Santhanam, Romina Libster, Bronner P. Gonçalves, Shabir A. Madhi, Azucena Bardají, Eva Mwangome, Adam Mabrouk, Hima B. John, Clara Sánchez Yanotti, Jaya Chandna, Pamela Sithole, Humberto Mucasse, Patrick V. Katana, Artemis Koukounari, Lois M. Harden, Celine Aerts, Azra Ghoor, Shannon Leahy, Sibongile Mbatha, Sarah Lowick, Sanjay G. Lala, Justina Bramugy, Charles Newton, A. K. M. Tanvir Hossain, Qazi Sadeq-ur Rahman, Philipp Lambach, Mark Jit, Joy E. Lawn
• Format: Article
• Language: English
• Published: F1000 Research Ltd 2021-07-01
• Series: Gates Open Research
• Online Access: https://gatesopenresearch.org/articles/4-138/v2

Sepsis and meningitis due to invasive group B Streptococcus (iGBS) disease during early infancy is a leading cause of child mortality. Recent systematic estimates of the worldwide burden of GBS suggested that there are 319,000 cases of infant iGBS disease each year, and an estimated 147,000 stillbirths and young-infant deaths, with the highest burden occurring in Sub-Saharan Africa.  The following priority data gaps were highlighted: (1) long-term outcome data after infant iGBS, including mild disability, to calculate quality-adjusted life years (QALYs) or disability-adjusted life years (DALYs) and (2) economic burden for iGBS survivors and their families. Geographic data gaps were also noted with few studies from low- and middle- income countries (LMIC), where the GBS burden is estimated to be the highest. In this paper we present the protocol for a multi-country matched cohort study designed to estimate the risk of long-term neurodevelopmental impairment (NDI), socioemotional behaviors, and economic outcomes for children who survive invasive GBS disease in Argentina, India, Kenya, Mozambique, and South Africa. Children will be identified from health demographic surveillance systems, hospital records, and among participants of previous epidemiological studies. The children will be aged between 18 months to 17 years. A tablet-based custom-designed application will be used to capture data from direct assessment of the child and interviews with the main caregiver. In addition, a parallel sub-study will prospectively measure the acute costs of hospitalization due to neonatal sepsis or meningitis, irrespective of underlying etiology. In summary, these data are necessary to characterize the consequences of iGBS disease and enable the advancement of effective strategies for survivors to reach their developmental and economic potential. In particular, our study will inform the development of a full public health value proposition on maternal GBS immunization that is being coordinated by the World Health Organization.